Academic Journal
Προβολή σε EDS

Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.
Συγγραφείς: Seguchi K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Hashimoto T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan., Fujisawa T; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Shibuki T; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Morizane C; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan., Nonomura N; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan., Iwata H; Department of Advanced Clinical Research and Development, Nagoya City University, Nagoya, Japan., Watari H; Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan., Okano S; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Namikawa K; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan., Naito Y; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Bando H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tyoshino@east.ncc.go.jp.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan. tyoshino@east.ncc.go.jp.
Πηγή: International journal of clinical oncology [Int J Clin Oncol] 2026 Aug; Vol. 31 (8), pp. 1431-1440. Date of Electronic Publication: 2026 Jun 06.
Τύπος έκδοσης: Journal Article; Observational Study; Multicenter Study; Review
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE
Imprint Name(s): Publication: 1998- : Tokyo : Springer-Verlag Tokyo
Original Publication: Tokyo : Published for the Japan Society of Clinical Oncology by Churchill Livingstone, c1996-
Ιατρικοί όροι (MeSH): Colorectal Neoplasms*/mortality , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/therapy , Colorectal Neoplasms*/genetics , Oncologists*/standards , Certification*, Japan/epidemiology ; Humans ; Female ; Male ; Retrospective Studies ; Aged ; Middle Aged ; Neoplasm Metastasis
Περίληψη: Background: Board certification in surgical oncology improves cancer outcomes, but the impact of medical oncologist certification on systemic therapy outcomes is unknown. We investigated whether the Japanese Society of Medical Oncology (JSMO) board certification of the enrolling physician was associated with treatment quality and survival.
Methods: This retrospective cohort study used data from the SCRUM-Japan MONSTAR-SCREEN observational study, a nationwide multicenter genomic screening program enrolling patients from 2019 to 2022. Standard treatment implementation rates were compared across cancer types as a secondary outcome. The primary outcome was overall survival (OS) in patients with metastatic colorectal cancer (mCRC) using Kaplan-Meier analysis and Cox proportional hazards regression with sequential adjustment for clinical and molecular covariates.
Results: Among 2,184 patients, standard treatment rates were comparable between board-certified and non-board-certified groups (97.0% vs. 96.9%). In 358 patients with mCRC, enrollment by a board-certified physician was associated with longer OS (median, 36.5 vs. 30.7 months; hazard ratio (HR): 0.66, 95% CI 0.50-0.87; log-rank p = 0.003) even after adjustment for age, sex, tumor sidedness, region, trial participation, molecular targeted therapy, metastatic organ count (HR, 0.73; 95% CI 0.55-0.97; p = 0.029), and after additional adjustment for RAS and BRAF V600E status (HR, 0.64; 95% CI 0.47-0.88; p = 0.005). Board-certified physicians used molecular targeted therapy more frequently (89.5% vs. 80.4%; p = 0.036).
Conclusions: JSMO board certification was independently associated with improved OS in mCRC despite comparable guideline adherence, suggesting that specialist expertise extends beyond treatment selection.
(© 2026. The Author(s).)
Competing Interests: Declarations. Conflict of interest: T. Hashimoto reports speakers’ bureau from CytoGen, Myriad Genetics, Inc., Miyarisan Pharmaceutical, Inc., Guardant Health Pte Ltd., Takeda Pharmaceutical, and Takata Pharmaceutical; research funding from Takeda Pharmaceutical and TEMPUS, Inc.; and advisory role with Guardant Health Pte Ltd. T. Fujisawa reports honoraria from Amelieff, AstraZeneca, and MSD. T. Shibuki reports personal fees from AstraZeneca and Novartis Pharma. S. Okano reports personal fees from Taiho Pharmaceutical, Eisai, Bayer Yakuhin, Chugai Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, MSD, Incyte, and Nihon Servier. C. Morizane reports grants from Eisai, Yakult, Ono, Taiho, J-Pharma, AstraZeneca, Merck, Daiichi Sankyo, and Boehringer Ingelheim; consulting fees from Yakult, MSD, Nihon Servier, Boehringer Ingelheim, and Taiho; and honoraria from Novartis, Yakult, Teijin Pharma, Taiho, Eisai, MSD, and AstraZeneca. N. Nonomura reports lecturer fees from Janssen, Pfizer, Astellas, Takeda, Ono, Novartis, MSD, AstraZeneca, Merck, Bayer, Bristol-Myers Squibb (BMS); and research expenses from J-Oil Mills, Taiho, Nippon Shinyaku, Pfizer, Astellas, and AstraZeneca. H. Iwata reports grant from Chugai, Daiichi Sankyo, and AstraZeneca; consulting fees from Chugai, Daiichi Sankyo, AstraZeneca, MSD, Eli Lilly, Pfizer, and Gilead; and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. H. Watari reports honoraria from AstraZeneca, Takeda, MSD, and Chugai. K. Namikawa reports honoraria from Ono, Novartis, BMS, MSD, LEO Pharma, and Kaken Pharmaceutical; served as an advisory board for Novartis, MSD, Rakuten Medical, Taiho, and Chugai; and received institutional research grants from HUYABIO International, Takara Bio, MSD, and Toray Industries. Y. Naito reports research funding (to institution) from AbbVie, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai Pharmaceutical, Bayer, Takeda Pharmaceutical, Anthos Therapeutics, and Gilead Sciences; consulting fees from AstraZeneca, Eisai, Gilead Sciences, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, Taiho Pharmaceutical, Bayer, Daiichi Sankyo, and Ono Pharmaceutical; and speakers’ bureau from AstraZeneca, Eisai, Ono Pharmaceutical, Guardant Health, Takeda Pharmaceutical, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, PDR Pharma, Nihon Kayaku, Taiho Pharmaceutical, Bristol Myers Squibb, Bayer, Daiichi Sankyo, MSD, and Gilead Sciences. H.Bando reports honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, and Guardant Health. T. Yoshino reports honoraria from Chugai, Takeda, Merck, and Ono; consulting fees from Sumitomo Corp, and Indivumed; and research grants from Bristol-Myers, Chugai, Caris, Daiichi Sankyo, Eisai, Exact Sciences, FALCO Biosystems, Medical & Biological Laboratories, Merus N.V., MSD, Miyarisan, Natera, Nippon Boehringer Ingelheim, Ono, Pfizer, Sysmex, Taiho, and Takeda. The other authors declare no potential conflicts of interest.
References: JAMA. 2023 Apr 18;329(15):1271-1282. (PMID: 37071094)
Esophagus. 2024 Oct;21(4):411-418. (PMID: 39158676)
J Clin Oncol. 2000 Jun;18(11):2327-40. (PMID: 10829054)
Breast Cancer. 2021 May;28(3):698-709. (PMID: 33398775)
J Gynecol Oncol. 2018 Mar;29(2):e23. (PMID: 29400016)
JCO Glob Oncol. 2024 Oct;10:e2400333. (PMID: 39509661)
Cancer Sci. 2021 Nov;112(11):4425-4432. (PMID: 34510657)
Oncologist. 2021 Sep;26(9):e1609-e1618. (PMID: 33973301)
Ann Intern Med. 2017 Aug 15;167(4):268-274. (PMID: 28693043)
J Surg Oncol. 2012 Sep 1;106(3):219-23. (PMID: 22105839)
Nat Med. 2020 Dec;26(12):1859-1864. (PMID: 33020649)
Clin Lung Cancer. 2017 Nov;18(6):706-718. (PMID: 28601387)
Surg Endosc. 2021 Oct;35(10):5480-5488. (PMID: 32989545)
Ann Oncol. 2018 Jan 1;29(1):44-70. (PMID: 29155929)
Adv Radiat Oncol. 2022 Mar 08;7(5):100938. (PMID: 35469182)
Gan To Kagaku Ryoho. 2024 Jan;51(1):45-52. (PMID: 38247091)
J Natl Cancer Inst. 2006 Feb 1;98(3):172-80. (PMID: 16449677)
JCO Glob Oncol. 2022 Mar;8:e2100314. (PMID: 35245099)
Gynecol Oncol. 2020 Jun;157(3):716-722. (PMID: 32217002)
Contributed Indexing: Keywords: Board certification; Chemotherapy; Colorectal cancer; Guideline adherence; Medical oncologist; Targeted therapy
Entry Date(s): Date Created: 20260606 Date Completed: 20260725 Latest Revision: 20260813
Update Code: 20260813
PubMed Central ID: PMC13401523
DOI: 10.1007/s10147-026-03069-0
PMID: 42250141
Βάση Δεδομένων: MEDLINE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://dx.doi.org/doi:10.1007/s10147-026-03069-0
    Name: EDS - Springer Nature Journals (s7799221)
    Category: fullText
    Text: View record at Springer
  – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:cmedm&genre=article&issn=14377772&ISBN=&volume=31&issue=8&date=20260801&spage=1431&pages=1431-1440&title=International journal of clinical oncology&atitle=Impact%20of%20medical%20oncologist%20certification%20on%20survival%20outcomes%20in%20metastatic%20colorectal%20cancer%3A%20evidence%20from%20the%20SCRUM-Japan%20MONSTAR-SCREEN%20Observational%20Study.&aulast=Seguchi%20K&id=DOI:10.1007/s10147-026-03069-0
    Name: Full Text Finder (for New FTF UI) (ns324271)
    Category: fullText
    Text: Full Text Finder
    MouseOverText: Full Text Finder
Header DbId: cmedm
DbLabel: MEDLINE
An: 42250141
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Seguchi+K%22">Seguchi K</searchLink>; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.<br /><searchLink fieldCode="AU" term="%22Hashimoto+T%22">Hashimoto T</searchLink>; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Fujisawa+T%22">Fujisawa T</searchLink>; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Shibuki+T%22">Shibuki T</searchLink>; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Morizane+C%22">Morizane C</searchLink>; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Nonomura+N%22">Nonomura N</searchLink>; Department of Urology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Iwata+H%22">Iwata H</searchLink>; Department of Advanced Clinical Research and Development, Nagoya City University, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Watari+H%22">Watari H</searchLink>; Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan.<br /><searchLink fieldCode="AU" term="%22Okano+S%22">Okano S</searchLink>; Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Namikawa+K%22">Namikawa K</searchLink>; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Naito+Y%22">Naito Y</searchLink>; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Bando+H%22">Bando H</searchLink>; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Yoshino+T%22">Yoshino T</searchLink>; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tyoshino@east.ncc.go.jp.; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan. tyoshino@east.ncc.go.jp.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229616295%22">International journal of clinical oncology</searchLink> [Int J Clin Oncol] 2026 Aug; Vol. 31 (8), pp. 1431-1440. <i>Date of Electronic Publication: </i>2026 Jun 06.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Observational Study; Multicenter Study; Review
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+Tokyo%22">Springer-Verlag Tokyo </searchLink><i>Country of Publication: </i>Japan <i>NLM ID: </i>9616295 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1437-7772 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213419625%22">13419625 </searchLink><i>NLM ISO Abbreviation: </i>Int J Clin Oncol <i>Subsets: </i>MEDLINE
– Name: PublisherInfo
  Label: Imprint Name(s)
  Group: PubInfo
  Data: <i>Publication</i>: 1998- : Tokyo : Springer-Verlag Tokyo<br /><i>Original Publication</i>: Tokyo : Published for the Japan Society of Clinical Oncology by Churchill Livingstone, c1996-
– Name: SubjectMESH
  Label: MeSH Terms
  Group: Su
  Data: <searchLink fieldCode="MM" term="%22Colorectal+Neoplasms%22">Colorectal Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Colorectal+Neoplasms+mortality%22">mortality</searchLink> <br /><searchLink fieldCode="MM" term="%22Colorectal+Neoplasms%22">Colorectal Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Colorectal+Neoplasms+pathology%22">pathology</searchLink> <br /><searchLink fieldCode="MM" term="%22Colorectal+Neoplasms%22">Colorectal Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Colorectal+Neoplasms+therapy%22">therapy</searchLink> <br /><searchLink fieldCode="MM" term="%22Colorectal+Neoplasms%22">Colorectal Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Colorectal+Neoplasms+genetics%22">genetics</searchLink> <br /><searchLink fieldCode="MM" term="%22Oncologists%22">Oncologists*</searchLink>/<searchLink fieldCode="MM" term="%22Oncologists+standards%22">standards</searchLink> <br /><searchLink fieldCode="MM" term="%22Certification%22">Certification*</searchLink><br /><searchLink fieldCode="MH" term="%22Japan%22">Japan</searchLink>/<searchLink fieldCode="MH" term="%22Japan+epidemiology%22">epidemiology</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Female%22">Female</searchLink> ; <searchLink fieldCode="MH" term="%22Male%22">Male</searchLink> ; <searchLink fieldCode="MH" term="%22Retrospective+Studies%22">Retrospective Studies</searchLink> ; <searchLink fieldCode="MH" term="%22Aged%22">Aged</searchLink> ; <searchLink fieldCode="MH" term="%22Middle+Aged%22">Middle Aged</searchLink> ; <searchLink fieldCode="MH" term="%22Neoplasm+Metastasis%22">Neoplasm Metastasis</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Board certification in surgical oncology improves cancer outcomes, but the impact of medical oncologist certification on systemic therapy outcomes is unknown. We investigated whether the Japanese Society of Medical Oncology (JSMO) board certification of the enrolling physician was associated with treatment quality and survival.<br />Methods: This retrospective cohort study used data from the SCRUM-Japan MONSTAR-SCREEN observational study, a nationwide multicenter genomic screening program enrolling patients from 2019 to 2022. Standard treatment implementation rates were compared across cancer types as a secondary outcome. The primary outcome was overall survival (OS) in patients with metastatic colorectal cancer (mCRC) using Kaplan-Meier analysis and Cox proportional hazards regression with sequential adjustment for clinical and molecular covariates.<br />Results: Among 2,184 patients, standard treatment rates were comparable between board-certified and non-board-certified groups (97.0% vs. 96.9%). In 358 patients with mCRC, enrollment by a board-certified physician was associated with longer OS (median, 36.5 vs. 30.7 months; hazard ratio (HR): 0.66, 95% CI 0.50-0.87; log-rank p = 0.003) even after adjustment for age, sex, tumor sidedness, region, trial participation, molecular targeted therapy, metastatic organ count (HR, 0.73; 95% CI 0.55-0.97; p = 0.029), and after additional adjustment for RAS and BRAF V600E status (HR, 0.64; 95% CI 0.47-0.88; p = 0.005). Board-certified physicians used molecular targeted therapy more frequently (89.5% vs. 80.4%; p = 0.036).<br />Conclusions: JSMO board certification was independently associated with improved OS in mCRC despite comparable guideline adherence, suggesting that specialist expertise extends beyond treatment selection.<br /> (© 2026. The Author(s).)
– Name: Abstract
  Label: Competing Interests
  Group: Ab
  Data: Declarations. Conflict of interest: T. Hashimoto reports speakers’ bureau from CytoGen, Myriad Genetics, Inc., Miyarisan Pharmaceutical, Inc., Guardant Health Pte Ltd., Takeda Pharmaceutical, and Takata Pharmaceutical; research funding from Takeda Pharmaceutical and TEMPUS, Inc.; and advisory role with Guardant Health Pte Ltd. T. Fujisawa reports honoraria from Amelieff, AstraZeneca, and MSD. T. Shibuki reports personal fees from AstraZeneca and Novartis Pharma. S. Okano reports personal fees from Taiho Pharmaceutical, Eisai, Bayer Yakuhin, Chugai Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, MSD, Incyte, and Nihon Servier. C. Morizane reports grants from Eisai, Yakult, Ono, Taiho, J-Pharma, AstraZeneca, Merck, Daiichi Sankyo, and Boehringer Ingelheim; consulting fees from Yakult, MSD, Nihon Servier, Boehringer Ingelheim, and Taiho; and honoraria from Novartis, Yakult, Teijin Pharma, Taiho, Eisai, MSD, and AstraZeneca. N. Nonomura reports lecturer fees from Janssen, Pfizer, Astellas, Takeda, Ono, Novartis, MSD, AstraZeneca, Merck, Bayer, Bristol-Myers Squibb (BMS); and research expenses from J-Oil Mills, Taiho, Nippon Shinyaku, Pfizer, Astellas, and AstraZeneca. H. Iwata reports grant from Chugai, Daiichi Sankyo, and AstraZeneca; consulting fees from Chugai, Daiichi Sankyo, AstraZeneca, MSD, Eli Lilly, Pfizer, and Gilead; and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. H. Watari reports honoraria from AstraZeneca, Takeda, MSD, and Chugai. K. Namikawa reports honoraria from Ono, Novartis, BMS, MSD, LEO Pharma, and Kaken Pharmaceutical; served as an advisory board for Novartis, MSD, Rakuten Medical, Taiho, and Chugai; and received institutional research grants from HUYABIO International, Takara Bio, MSD, and Toray Industries. Y. Naito reports research funding (to institution) from AbbVie, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai Pharmaceutical, Bayer, Takeda Pharmaceutical, Anthos Therapeutics, and Gilead Sciences; consulting fees from AstraZeneca, Eisai, Gilead Sciences, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, Taiho Pharmaceutical, Bayer, Daiichi Sankyo, and Ono Pharmaceutical; and speakers’ bureau from AstraZeneca, Eisai, Ono Pharmaceutical, Guardant Health, Takeda Pharmaceutical, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, PDR Pharma, Nihon Kayaku, Taiho Pharmaceutical, Bristol Myers Squibb, Bayer, Daiichi Sankyo, MSD, and Gilead Sciences. H.Bando reports honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, and Guardant Health. T. Yoshino reports honoraria from Chugai, Takeda, Merck, and Ono; consulting fees from Sumitomo Corp, and Indivumed; and research grants from Bristol-Myers, Chugai, Caris, Daiichi Sankyo, Eisai, Exact Sciences, FALCO Biosystems, Medical & Biological Laboratories, Merus N.V., MSD, Miyarisan, Natera, Nippon Boehringer Ingelheim, Ono, Pfizer, Sysmex, Taiho, and Takeda. The other authors declare no potential conflicts of interest.
– Name: Ref
  Label: References
  Group: RefInfo
  Data: JAMA. 2023 Apr 18;329(15):1271-1282. (PMID: <searchLink fieldCode="PM" term="%2237071094%22">37071094)</searchLink><br />Esophagus. 2024 Oct;21(4):411-418. (PMID: <searchLink fieldCode="PM" term="%2239158676%22">39158676)</searchLink><br />J Clin Oncol. 2000 Jun;18(11):2327-40. (PMID: <searchLink fieldCode="PM" term="%2210829054%22">10829054)</searchLink><br />Breast Cancer. 2021 May;28(3):698-709. (PMID: <searchLink fieldCode="PM" term="%2233398775%22">33398775)</searchLink><br />J Gynecol Oncol. 2018 Mar;29(2):e23. (PMID: <searchLink fieldCode="PM" term="%2229400016%22">29400016)</searchLink><br />JCO Glob Oncol. 2024 Oct;10:e2400333. (PMID: <searchLink fieldCode="PM" term="%2239509661%22">39509661)</searchLink><br />Cancer Sci. 2021 Nov;112(11):4425-4432. (PMID: <searchLink fieldCode="PM" term="%2234510657%22">34510657)</searchLink><br />Oncologist. 2021 Sep;26(9):e1609-e1618. (PMID: <searchLink fieldCode="PM" term="%2233973301%22">33973301)</searchLink><br />Ann Intern Med. 2017 Aug 15;167(4):268-274. (PMID: <searchLink fieldCode="PM" term="%2228693043%22">28693043)</searchLink><br />J Surg Oncol. 2012 Sep 1;106(3):219-23. (PMID: <searchLink fieldCode="PM" term="%2222105839%22">22105839)</searchLink><br />Nat Med. 2020 Dec;26(12):1859-1864. (PMID: <searchLink fieldCode="PM" term="%2233020649%22">33020649)</searchLink><br />Clin Lung Cancer. 2017 Nov;18(6):706-718. (PMID: <searchLink fieldCode="PM" term="%2228601387%22">28601387)</searchLink><br />Surg Endosc. 2021 Oct;35(10):5480-5488. (PMID: <searchLink fieldCode="PM" term="%2232989545%22">32989545)</searchLink><br />Ann Oncol. 2018 Jan 1;29(1):44-70. (PMID: <searchLink fieldCode="PM" term="%2229155929%22">29155929)</searchLink><br />Adv Radiat Oncol. 2022 Mar 08;7(5):100938. (PMID: <searchLink fieldCode="PM" term="%2235469182%22">35469182)</searchLink><br />Gan To Kagaku Ryoho. 2024 Jan;51(1):45-52. (PMID: <searchLink fieldCode="PM" term="%2238247091%22">38247091)</searchLink><br />J Natl Cancer Inst. 2006 Feb 1;98(3):172-80. (PMID: <searchLink fieldCode="PM" term="%2216449677%22">16449677)</searchLink><br />JCO Glob Oncol. 2022 Mar;8:e2100314. (PMID: <searchLink fieldCode="PM" term="%2235245099%22">35245099)</searchLink><br />Gynecol Oncol. 2020 Jun;157(3):716-722. (PMID: <searchLink fieldCode="PM" term="%2232217002%22">32217002)</searchLink>
– Name: SubjectMinor
  Label: Contributed Indexing
  Group:
  Data: <i>Keywords: </i>Board certification; Chemotherapy; Colorectal cancer; Guideline adherence; Medical oncologist; Targeted therapy
– Name: DateEntry
  Label: Entry Date(s)
  Group: Date
  Data: <i>Date Created: </i>20260606 <i>Date Completed: </i>20260725 <i>Latest Revision: </i>20260813
– Name: DateUpdate
  Label: Update Code
  Group: Date
  Data: 20260813
– Name: PubmedCentralID
  Label: PubMed Central ID
  Group: ID
  Data: PMC13401523
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1007/s10147-026-03069-0
– Name: AN
  Label: PMID
  Group: ID
  Data: 42250141
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=42250141
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10147-026-03069-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1431
    Subjects:
      – SubjectFull: Japan epidemiology
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Female
        Type: general
      – SubjectFull: Male
        Type: general
      – SubjectFull: Retrospective Studies
        Type: general
      – SubjectFull: Aged
        Type: general
      – SubjectFull: Middle Aged
        Type: general
      – SubjectFull: Neoplasm Metastasis
        Type: general
      – SubjectFull: Colorectal Neoplasms mortality
        Type: general
      – SubjectFull: Colorectal Neoplasms pathology
        Type: general
      – SubjectFull: Colorectal Neoplasms therapy
        Type: general
      – SubjectFull: Colorectal Neoplasms genetics
        Type: general
      – SubjectFull: Oncologists standards
        Type: general
      – SubjectFull: Certification
        Type: general
    Titles:
      – TitleFull: Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Seguchi K
      – PersonEntity:
          Name:
            NameFull: Hashimoto T
      – PersonEntity:
          Name:
            NameFull: Fujisawa T
      – PersonEntity:
          Name:
            NameFull: Shibuki T
      – PersonEntity:
          Name:
            NameFull: Morizane C
      – PersonEntity:
          Name:
            NameFull: Nonomura N
      – PersonEntity:
          Name:
            NameFull: Iwata H
      – PersonEntity:
          Name:
            NameFull: Watari H
      – PersonEntity:
          Name:
            NameFull: Okano S
      – PersonEntity:
          Name:
            NameFull: Namikawa K
      – PersonEntity:
          Name:
            NameFull: Naito Y
      – PersonEntity:
          Name:
            NameFull: Bando H
      – PersonEntity:
          Name:
            NameFull: Yoshino T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2026 Aug
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1437-7772
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: International journal of clinical oncology
              Type: main
ResultId 1